Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis;Comparação entre o uso tópico do fumarato de cetotifeno 0,025% e do cloridrato de olopatadina 0,1% no tratamento da ceratoconjuntivite primaveril

Arquivos Brasileiros de Oftalmologia

Volumn 69, Issue 6, 2006, Pages 851-856

  Hida, Wilson Takashi ^a,c   Nogueira, Daniel Cruz ^a   Schaefer, Arthur ^a   Correa Dantas, Paulo Elias ^b   Nishiwaki Dantas, Maria Cristina ^a,b  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Santa Casa de São Paulo ^*  (Brazil)

Author keywords

Allergic drug therapy; Conjunctivitis; Dibenzoxepins therapeutic use; Drug combinations; Ketotifen therapeutic use; Ophthalmic solutions

Indexed keywords

EID: 33846807491     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492006000600013     Document Type: Article

References (19)

1. Holzchuh N, Kara-Jose N, Alves MR. Alergia. In: Belfort RJ, Kara-Jose N, editores. Córnea: clínica e cirúrgica. São Paulo: Roca, 1997. p.254-6.
2. Goulart DA, Goulart D, Cypel MC, Dantas PEC, Nishiwaki-Dantas MC. Perfil clínico-epidemiológico de pacientes do Ambulatório de Alergia ocular da Santa Casa de São Paulo. Arq Bras Oftalmol. 2003;66(5):609-15.
3. Messmer EM. [Ocular allergies] Ophthalmologe. 2005;102(5):527-43; quiz 544. German.
4. Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005;10(3):505-20.
5. Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye. 2004;18(4):345-51.
6. Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand Suppl. 1999;(228):33-7.
7. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998;125(6):797-804.
8. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998;81(3):211-8.
9. Heyman SN, Karmeli F, Brezis M, Rachmilewitz D. The effect of ketotifen on nitric oxide synthase activity. Br J Pharmacol. 1997;120(8):1545-51.
10. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther. 2003;25 (10):2539-52.
11. Greiner JV, Mundorf T, Dubiner H, Lonsdale J, Casey R, Parver L, et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am J Ophthalmol. 2003; 136(6):1097-105.
12. Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr Allergy Immunol. 2004;15(6):551-7.
13. Ganz M, Koll E, Gausche J, Detjen P, Orfan N. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. Adv Ther. 2003;20(2):79-91.
14. Höfling-Lima AL, Andrade AJM, Marback PMF, Farah ME, Mascaro V. Comparação do uso tópico de cetotifeno com a olopatadina no tratamento de conjuntivites alérgica. Arq Bras Oftalmol. 2001:64(5):415-22.
15. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin. 2004;20(8):1167-73.
16. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl. 2000(230):52-5.
17. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther. 2000;22(7):826-33.
18. Joyce PD. Corneal vital staining. Ir J Med Sci 1967;6(500):359-67.
19. Bar-Ilan A, Nuemann R. Basic considerations of ocular drug-delivery systems. In: Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997. p.139-55.